Sep 26, 2025 04:34PM Silexion Therapeutics (SLXN) files $100M mixed shelf

Sep 11, 2025 07:02AM Silexion reports preclinical data showing SIL204 reaches pancreatic cancer sites

Jul 31, 2025 09:58AM Silexion reports up to 97% cancer cell growth inhibition in preclinical study

Jul 16, 2025 08:44AM Silexion Therapeutics implements 1-for-15 reverse stock split

Jul 9, 2025 08:35AM Silexion reports positive preclinical results for lung cancer drug SIL204

May 29, 2025 09:06AM Silexion Therapeutics (SLXN) Reports Preclinical Results for SIL204

May 21, 2025 08:46AM Silexion Therapeutics (SLXN) Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

Apr 23, 2025 09:21AM Silexion Therapeutics (SLXN) partners with Catalent for development and manufacturing

Mar 28, 2025 08:31AM Silexion Therapeutics (SLXN) Unveils Innovative Expanded Development Plan for SIL204

Mar 27, 2025 04:19PM Silexion Therapeutics (SLXN) Files for 2.38M Share Offering by Selling Stockholders

Mar 5, 2025 08:31AM Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Jan 28, 2025 08:29AM Silexion Therapeutics (SLXN) Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 15, 2025 04:02PM Sielox, Inc. (SLXN) Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Dec 17, 2024 06:31AM Sielox (SLXN) collaborates with Evonik on advanced siRNA Formulation Development

Oct 1, 2024 06:45AM Sielox, Inc. (SLXN) Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024 07:34AM Sielox, Inc. (SLXN) Announces Significant New Data from Phase 2 Trial of LODER

Sep 10, 2024 06:25AM Silexion Therapeutics (SLXN) Files for 15.38M Share Offering by Selling Stockholders